Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 230

1.

Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis.

Al-Ruwaili JA, Larkin SE, Zeidan BA, Taylor MG, Adra CN, Aukim-Hastie CL, Townsend PA.

Cancer Genomics Proteomics. 2010 Mar-Apr;7(2):93-103.

PMID:
20335524
2.
3.

[Proteomic analysis of prostate cancer using surface enhanced laser desorption/ionization mass spectrometry].

Pan YZ, Xiao XY, Zhao D, Zhang L, Ji GY, Li Y, He DC, Zhao XJ, Yang BX.

Zhonghua Yi Xue Za Zhi. 2005 Nov 30;85(45):3172-5. Chinese.

PMID:
16405834
4.

Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.

Ornstein DK, Rayford W, Fusaro VA, Conrads TP, Ross SJ, Hitt BA, Wiggins WW, Veenstra TD, Liotta LA, Petricoin EF 3rd.

J Urol. 2004 Oct;172(4 Pt 1):1302-5.

PMID:
15371828
5.

A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection.

Yasui Y, Pepe M, Thompson ML, Adam BL, Wright GL Jr, Qu Y, Potter JD, Winget M, Thornquist M, Feng Z.

Biostatistics. 2003 Jul;4(3):449-63.

PMID:
12925511
6.

Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples.

Freed GL, Cazares LH, Fichandler CE, Fuller TW, Sawyer CA, Stack BC Jr, Schraff S, Semmes OJ, Wadsworth JT, Drake RR.

Laryngoscope. 2008 Jan;118(1):61-8.

PMID:
18043497
7.

Five serum proteins identified using SELDI-TOF-MS as potential biomarkers of gastric cancer.

Lu HB, Zhou JH, Ma YY, Lu HL, Tang YL, Zhang QY, Zhao CH.

Jpn J Clin Oncol. 2010 Apr;40(4):336-42. doi: 10.1093/jjco/hyp175. Epub 2010 Jan 20.

PMID:
20089528
8.

Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer.

Chung L, Moore K, Phillips L, Boyle FM, Marsh DJ, Baxter RC.

Breast Cancer Res. 2014 Jun 16;16(3):R63. doi: 10.1186/bcr3676.

9.
10.

Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel- and lectin-based proteomics analyses.

Jayapalan JJ, Ng KL, Razack AH, Hashim OH.

Electrophoresis. 2012 Jul;33(12):1855-62. doi: 10.1002/elps.201100608.

PMID:
22740474
11.

Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.

Han KQ, Huang G, Gao CF, Wang XL, Ma B, Sun LQ, Wei ZJ.

Am J Clin Oncol. 2008 Apr;31(2):133-9. doi: 10.1097/COC.0b013e318145b98b.

PMID:
18391596
12.

Predicting early intrahepatic recurrence of hepatocellular carcinoma after microwave ablation using SELDI-TOF proteomic signature.

Cao XL, Li H, Yu XL, Liang P, Dong BW, Fan J, Li M, Liu FY.

PLoS One. 2013 Dec 13;8(12):e82448. doi: 10.1371/journal.pone.0082448. eCollection 2013.

13.

Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling.

Ehmann M, Felix K, Hartmann D, Schnölzer M, Nees M, Vorderwülbecke S, Bogumil R, Büchler MW, Friess H.

Pancreas. 2007 Mar;34(2):205-14.

PMID:
17312459
14.
15.

Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.

Pang J, Liu WP, Liu XP, Li LY, Fang YQ, Sun QP, Liu SJ, Li MT, Su ZL, Gao X.

J Proteome Res. 2010 Jan;9(1):216-26. doi: 10.1021/pr900953s.

PMID:
19894759
16.

Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions.

Le L, Chi K, Tyldesley S, Flibotte S, Diamond DL, Kuzyk MA, Sadar MD.

Clin Chem. 2005 Apr;51(4):695-707. Epub 2005 Feb 3.

17.

Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform.

Ummanni R, Mundt F, Pospisil H, Venz S, Scharf C, Barett C, Fälth M, Köllermann J, Walther R, Schlomm T, Sauter G, Bokemeyer C, Sültmann H, Schuppert A, Brümmendorf TH, Balabanov S.

PLoS One. 2011 Feb 11;6(2):e16833. doi: 10.1371/journal.pone.0016833.

18.

Identification of serum biomarkers for nasopharyngeal carcinoma by proteomic analysis.

Wei YS, Zheng YH, Liang WB, Zhang JZ, Yang ZH, Lv ML, Jia J, Zhang L.

Cancer. 2008 Feb 1;112(3):544-51.

19.

SELDI-TOF serum proteomics and colorectal cancer: a current overview.

Gemoll T, Roblick UJ, Auer G, Jörnvall H, Habermann JK.

Arch Physiol Biochem. 2010 Oct-Dec;116(4-5):188-96. doi: 10.3109/13813455.2010.495130. Epub 2010 Jul 8. Review.

PMID:
20615064
20.

Diagnostic potential of serum proteomic patterns in prostate cancer.

Bañez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam BL, McLeod DG, Moul JW, Srivastava S.

J Urol. 2003 Aug;170(2 Pt 1):442-6.

PMID:
12853795

Supplemental Content

Support Center